Phaxiam Therapeutics says it has notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares representing its ordinary shares, which should be effective.
04.10.2023 - PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has .
Pharmaceutical companies are investing heavily in the Acute Lymphoblastic Leukemia market, resulting in an expanding range of treatment options and a brighter outlook for patients.Wilmington, Delaware, United States, Oct. 05, 2023 (GLOBE NEWSWIRE) Transparency Market Research Inc. - The acute lymphoblastic leukemia market was estimated to have acquired US$ 2.2 billion in 2021. It is anticipated to register a 7.6% CAGR from 2022 to 2031 and by 2031; the market is likely to gain US$ 4.5 billion
PHAXIAM Receives Compliance Notice from Nasdaq marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.